Viatris (XSWX:VTRS) Tariff Resilience Score: 7/10 (As of Jul. 02, 2026)


XSWX:VTRS Viatris Inc XSWX:VTRS
60 GF Score
Price CHF13.06
GF Value CHF8.89
! 8 Warning Signs
View Full Analysis

What is Viatris Tariff Resilience Score?

Viatris XSWX:VTRS +0.62% 60 Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.89. The stock has 8 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Viatris ranks better than 97.08% on this metric.

Viatris has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Viatris has Viatris has a global supply chain with manufacturing in multiple countries. It faces tariff risks on pharmaceuticals but has diversified production and strong pricing power to mitigate impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Viatris might have Highly Resilient.

Viatris  (XSWX:VTRS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Viatris Tariff Resilience Score Related Terms

XSWX:VTRS vs NBIX, UTHR, ELAN: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Viatris's Tariff Resilience Score falls into.


XSWX:VTRS
60GF Score
Viatris Inc XSWX:VTRS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Viatris (XSWX:VTRS) has a Tariff Resilience Score of 7 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Viatris ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Viatris' Tariff Resilience Score too high?
Viatris' current Tariff Resilience Score is 7. Based on the distribution chart, Viatris ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Tariff Resilience Score compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #30 out of 1029 companies for Tariff Resilience Score. This places Viatris in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Viatris's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Tariff Resilience Score of 7. The stock's GF Value™ is CHF8.89, compared to a current price of CHF13.06 — trading 46.9% above its estimated fair value. The current Tariff Resilience Score is 7. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (XSWX:VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of CHF13.06 is trading 46.9% above its estimated GF Value™ of CHF8.89.

Key valuation signals for XSWX:VTRS:

  • Tariff Resilience Score: 7
  • GF Value™: CHF8.89 vs. price of CHF13.06 (46.9% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for XSWX:VTRS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.06
Price
CHF8.89
GF Value